Comparison of Neointimal Response between Durable-Polymer Everolimus-Eluting Stent and Bioabsorbable-Polymer Everolimus-Eluting Stent for Severely Calcified Lesions Requiring Rotational Atherectomy.


Journal

International heart journal
ISSN: 1349-3299
Titre abrégé: Int Heart J
Pays: Japan
ID NLM: 101244240

Informations de publication

Date de publication:
30 Jul 2020
Historique:
pubmed: 21 7 2020
medline: 13 8 2020
entrez: 21 7 2020
Statut: ppublish

Résumé

Clinical outcomes after percutaneous coronary intervention (PCI) for severely calcified lesions remain poor. The purpose of this study was to investigate the neointimal response after everolimus-eluting stents (EES) for severely calcified lesions treated with rotational atherectomy (RA) using optical coherence tomography (OCT).We retrospectively analyzed 34 lesions in which PCI was performed with EES deployment following RA and OCT was performed immediately after PCI and at follow-up (nine months). The EES was either durable-polymer (DP) EES (22 lesions) or bioabsorbable polymer (BP) -EES (12 lesions). Strut coverage and malapposition were evaluated at 1-mm intervals of cross-section (CS) by serial OCT analysis. Malapposed strut was defined as having the distance from luminal border > 100 μm.A total of 11,823 struts immediately after PCI and 11,720 struts at follow-up were analyzed. Immediately after PCI, the strut-level analysis showed no significant differences in the percentage of malapposed struts between the DP-EES group and the BP-EES group. At follow-up, the BP-EES group showed a more prevalent covered strut compared with the DP-EES group (strut-level analysis: 95% versus 97%, P = 0.045; CS-level analysis: 97% versus 100%, P < 0.01; lesion-level analysis: 27% versus 83%, P < 0.01, respectively).In severely calcified lesions requiring RA, the BP-EES group achieved better neointimal coverage than the DP-EES group at nine months. Additional prospective studies are needed.

Identifiants

pubmed: 32684594
doi: 10.1536/ihj.19-648
doi:

Substances chimiques

Antineoplastic Agents 0
Polymers 0
Everolimus 9HW64Q8G6G

Types de publication

Comparative Study Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

665-672

Auteurs

Yuji Matsuda (Y)

Department of Cardiovascular Medicine, Graduate School of Medical and Dental Science, Tokyo Medical and Dental University.

Takashi Ashikaga (T)

Department of Cardiology, Japanese Red Cross Musashino Hospital.
Department of Cardiovascular Medicine, Faculty of Medicine, Tokyo Medical and Dental University.

Taro Sasaoka (T)

Department of Cardiovascular Medicine, Faculty of Medicine, Tokyo Medical and Dental University.

Yu Hatano (Y)

Department of Cardiovascular Medicine, Faculty of Medicine, Tokyo Medical and Dental University.

Tomoyuki Umemoto (T)

Department of Cardiovascular Medicine, Faculty of Medicine, Tokyo Medical and Dental University.

Tetsumin Lee (T)

Department of Cardiovascular Medicine, Faculty of Medicine, Tokyo Medical and Dental University.

Taishi Yonetsu (T)

Department of Cardiovascular Medicine, Faculty of Medicine, Tokyo Medical and Dental University.

Yasuhiro Maejima (Y)

Department of Cardiovascular Medicine, Faculty of Medicine, Tokyo Medical and Dental University.

Tetsuo Sasano (T)

Department of Cardiovascular Medicine, Graduate School of Medical and Dental Science, Tokyo Medical and Dental University.
Department of Cardiovascular Medicine, Faculty of Medicine, Tokyo Medical and Dental University.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH